Jazz Pharmaceuticals Plc (JAZZ) had the kind of Monday that biotech companies dream about. The stock surged more than 20% after the company reported positive Phase 3 trial results that could reshape treatment options for patients with advanced gastroesophageal cancer.

The Trial Results That Moved Markets

Jazz's HERIZON-GEA-01 trial tested Ziihera combined with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. That's a mouthful, but it covers cancers of the esophagus, stomach, and gastroesophageal junction—areas where treatment options remain limited.

The results were compelling. Both treatment combinations beat the control group (which received trastuzumab and chemotherapy) with statistically and clinically significant improvements in progression-free survival. That means patients went longer without their cancer worsening.

The triple combination of Ziihera, tislelizumab, and chemotherapy delivered even better news: a statistically significant and clinically meaningful increase in overall survival. The Ziihera-plus-chemotherapy arm also showed a strong trend toward statistical significance for overall survival, with a follow-up interim analysis planned for mid-2026.

What The Experts Are Saying

According to Dr. Kohei Shitara, director of the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, "zanidatamab plus chemotherapy combination, with and without tislelizumab, has the potential to become the new standard of care for patients in HER2+ first-line locally advanced unresectable or metastatic GEA."

Rob Iannone, executive vice president and chief medical officer of Jazz Pharmaceuticals, was equally optimistic. "We believe these results will be practice changing, and highlight the potential impact of Ziihera for patients who are facing a devastating diagnosis and limited options in locally advanced or metastatic GEA," he said. "We expect Ziihera to become the new standard of care anti-HER2 therapy for patients with HER2+ first-line metastatic GEA regardless of PD-L1 status."

The Market Response

Jazz Pharmaceuticals shares climbed 20.49% to $170.11, hitting a new 52-week high as investors processed the implications of a potential blockbuster treatment entering the market.